Evaluation of Vascular Access Modality for Hemodialysis Patients: Analysis of Real-World Data in Italy

Author(s)

Monteverde Spencer GT1, Dovizio M2, Iacolare B2, Andretta M3, Bacca M4, Bartolini F5, Barbieri A6, Ciaccia A7, Chinellato A8, Costantini A9, De Vita F10, Gentile S11, Mancini D4, Mensurati M12, Moscogiuri R13, Mosele E14, Pagliaro R15, Petragnani N10, Re D16, Santoleri F9, Martoni M1, Di Stasi F1, Degli Esposti L2
1W. L. Gore & Associati S.r.l., Verona, Italy, 2CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, BO, Italy, 3Azienda ULSS 8 Berica, Vicenza, Italy, 4ASL Brindisi, Brindisi, Italy, 5USL Umbria 2, Terni, Italy, 6ASL Vercelli, Vercelli, Italy, 7Servizio Farmaceutico Territoriale ASL Foggia, Foggia, Italy, 8Azienda ULSS 3 Serenissima, Mestre (VE), Italy, 9ASL Pescara, Pescara, Italy, 10UOC Farmacia Ospedaliera, ASL Lanciano Vasto Chieti, Chieti, Italy, 11Direzione Generale per la Salute Regione Molise, Campobasso, Italy, 12ASL Roma 3, Roma, Italy, 13ASL Taranto, Taranto, Italy, 14UOC Assistenza Farmaceutica Territoriale Azienda ULSS 7 Pedemontana, Bassano del Grappa (VI), Italy, 15ASL Roma 5, Tivoli, Italy, 16ASL Teramo, Roseto degli Abruzzi, Italy

OBJECTIVES: The vascular access type has implications on successful hemodialysis. This real-world analysis investigated the vascular access dialysis types: central venous catheter (CVC), arteriovenous fistula (AVF) and arteriovenous graft (AVG) in an Italian clinical practice setting.

METHODS: A retrospective analysis was conducted on administrative databases of a sample of healthcare entities (geographically distributed across Italy), covering almost 10% of Italian population. Between 01/2009-08/2022, patients with ≥1 record of hemodialysis (procedure code 39.95 and/or hospitalization code V56.0) were included. The first hemodialysis record was the index-date; the vascular access type (CVC, AVF, AVG) was evaluated before and after the index-date.

RESULTS: 3,451 hemodialysis patients were included; 61.7% males, mean age of 68.7 years. Among them, 48.6% had a single vascular access implantation: 33.1% had CVC only, 14.7% AVF only and 0.8% AVG only. Considering patients with ≥1 vascular access type, 24.9% were implanted with both CVC and AVF [14.5% (N = 502) started with CVC followed by AVF (after a mean of 218 days), 10.4% (N = 360) started with AVF followed by CVC (after a mean of 664 days)] and 0.8% (N = 26) had CVC-AVF-AVG pathway (after a mean of 169 and 439 days, respectively). Among AVG users (N=191, 5.5%), 47% (N = 90) started with AVG and 53% (N = 101) had AVG after an AVF or CVC. Among patients who switched vascular access, the mean duration (days) on the first vascular access was 533 ± 768 for CVC, 913±936 for AVF and 688 ± 846 for AVG.

CONCLUSIONS: This real-world analysis shows vascular access types used in hemodialysis patients in Italy. Almost 50% of patients had a single vascular access implantation, almost 25% alternated CVC/AVF and 5.5% had AVG. These results could be informative on the management of hemodialysis patients in clinical practice in Italy.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

HSD19

Disease

Medical Devices, Urinary/Kidney Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×